CervoMed Inc. - Common Stock CRVO 深 滬
等待開盤 09-30 09:30:00 美东时间
8.08
-0.200
-2.42%
華盛通- 最 高8.37
- 今 開8.12
- 成交量 7.00万股
- 最 低 8.0729
- 昨 收 8.28
- 總市值 7476.18万
- 52周最高 16.94
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.80
- 委 比 85.89%
- 總股本 925.27万
- 歷史最高 17437.50
- 量 比 0.94
- 振 幅 3.59%
- 歷史最低 1.80
- 每 手 1
- 風險率 3.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CervoMed Highlights Dementia Drug Results at Major Neurology Conference
CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the promising development program and potential
09-17 19:42
CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
CervoMed Inc. announced that neflamapimod, a potential treatment for Dementia with Lewy Bodies (DLB), was highlighted at the 150th Annual American Neurological Association conference. Neflamapimod showed promising results in reducing the risk of disease worsening in a Phase 2b trial, with a 74% risk reduction compared to placebo in patients with pure DLB. The company is preparing for a Phase 3 trial, aiming to align with the FDA by year-end 2025....
09-17 11:30
HC Wainwright & Co. Reiterates Neutral on CervoMed, Announces $11 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Neutral and announces $11 price target.
09-08 18:55
CervoMed to Participate in Upcoming Investor Conferences
CervoMed Inc. announced that its management will participate in two investor conferences in September 2025: the H.C. Wainwright 27th Annual Global Investment Conference on September 8, featuring a presentation and 1x1 investor meetings, and Morgan Stanley's 23rd Annual Global Healthcare Conference from September 8-10, focusing on 1x1 investor meetings. CervoMed, a clinical-stage company developing treatments for age-related neurologic disorders, ...
09-03 12:00
D. Boral Capital Maintains Buy on CervoMed, Raises Price Target to $31
D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $15 to $31.
08-18 19:45
美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
08-13 09:10
Chardan Capital Maintains Buy on CervoMed, Maintains $15 Price Target
Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $15 price target.
08-11 19:46
CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
CervoMed reported positive data from the Phase 2b RewinD-LB Trial, showing that neflamapimod significantly reduced clinical worsening in Dementia with Lewy Bodies (DLB) patients, particularly in those with minimal Alzheimer’s co-pathology. The treatment also decreased biomarkers of neurodegeneration. The company plans to meet with the FDA in Q4 2025 to discuss Phase 3 trial design. Financially, CervoMed ended Q2 2025 with $33.5M in cash and repor...
08-11 12:00
CervoMed Q2 EPS $(0.70) Misses $(0.63) Estimate, Sales $1.758M Beat $1.734M Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.63) by 11.11 percent. This is a 159.26 percent decrease over losses of $(0.27) per share from the
08-08 21:57
CervoMed Shares Business and Financial Updates Online
CervoMed ( ($CRVO) ) has issued an announcement. CervoMed Inc. has made availab...
08-06 04:50
